Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
EBOI On Other Exchanges
Symbol
Exchange
OTC US
All times are local (Market data is delayed by at least 15 minutes).

enhance biotech inc (EBOI) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
55.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ENHANCE BIOTECH INC (EBOI)

Related News

No related news articles were found.

enhance biotech inc (EBOI) Related Businessweek News

No Related Businessweek News Found

enhance biotech inc (EBOI) Details

Enhance Biotech, Inc. acquires, develops, and commercializes therapeutic drugs. Its product pipeline includes products under development in three main groups: Urology, Dermatology, and Central Nervous System disorders. The company’s Urology products include LI-301 for the delay of ejaculation in men and DPI-221 for urinary incontinence. Its Dermatology products include LI-303 for cellulite, LI-312 for psoriasis and atopic dermatitis, LI-412 for eczema/itch, and LI-236 for anti-aging. The company also developsdrugs for treating Central Nervous System disorders, including cDPI-125 for moderate to severe pain, DPI-289 for depression, and DPI-290 for Parkinson’s disease. Its other products under development to license include LI-401 for the treatment of gingivitis and periodontitis in humans and animals; LI-316 {Stimulant} and LI-316{Inhibitor} for human male and animal fertility enhancement; and ARD-353 for cardiovascular disease. The company was formerly known as Enhance Lifesciences, Inc. and changed its name to Enhance Biotech, Inc. in April, 2003. Enhance Biotech, Inc. is headquartered in Durham, North Carolina.

15 Employees
Last Reported Date: 07/5/05

enhance biotech inc (EBOI) Top Compensated Officers

Chief Financial Officer
Total Annual Compensation: --
Chief Science Officer and President of Asia P...
Total Annual Compensation: --
Chief Science Officer and Vice President of S...
Total Annual Compensation: --
Secretary
Total Annual Compensation: --
Vice President
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EBOI:US $0.00 USD 0.00

EBOI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EBOI.
View Industry Companies
 

Industry Analysis

EBOI

Industry Average

Valuation EBOI Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENHANCE BIOTECH INC, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.